Jump to Main Contents
ncc en
HOME > Publication & Reports > Annual Report 2022 > Hospital

Annual Report 2022

Department of Infectious Diseases

Osamu Kobayashi, Mika Shiotsuka, Satoshi Iwata, Sayuri Hara, Mami Makino

Introduction

 The Department of Infectious Diseases supports clinical practice in relation to infectious diseases in National Cancer Center Hospital in cooperation with the Office of Infection Control and Prevention. We also conduct research activities for infectious diseases and vaccines in cooperation with other departments inside/outside the hospital. Our department consists of infectious disease specialists and office clerks.

The Team and What We Do

  • Advise on infection control and prevention, especially focusing on healthcare-associated infections, problematic pathogens including multidrug-resistant bacteria, and occupational infections.
  • Consult with physicians on appropriate diagnosis of and treatment for infectious diseases.
  • Implement antimicrobial stewardship strategy based on the local data from our hospital and the current clinical evidence.
  • Make weekly rounds in the wards to monitor the environmental maintenance and the compliance with the Infection Prevention and Control Manual.
  • Conduct surveillance for healthcare-associated infections and drug-resistant bacteria.
  • Provide education to the staff on standard practices regarding infection control and prevention with up-to-date evidence.
  • Check the immunization status of the hospital staff and vaccinate those with insufficient protective immunity.
  • Advise on building and refurbishment projects from the perspective of infection control.
  • Hold conferences or mutual site visits with other regional hospitals to promote improvement in one another’s infection control and prevention practices.

Research Activities

  • Effective education on infection control practices, especially medical device management.
  • Appropriate dosing of antimicrobial drugs in cancer patients.
  • Ideal system of infection control for cancer centers in the Japanese medical care system.

Education

 We provided training for infection control and management of infectious diseases aimed at physicians and medical personnel.

Future Prospects

 Our final goal is to establish an ideal and feasible model of an infection control system for cancer centers around the world and to develop human resources for management of infectious diseases, infection control and appropriate use of antimicrobial agents.

List of papers published in 2022

Journal

1. Fukuda A, Yoshida T, Yagishita S, Shiotsuka M, Kobayashi O, Iwata S, Umeguchi H, Yanagida M, Irino Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Yamamoto N, Ohe Y. Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan. Anticancer research, 43:919-926, 2023

2. Tanimura K, Nakajima M, Shirakawa N, Tao K, Sugiyama M, Watanabe Y, Arakawa A, Kikuchi M, Takahashi M, Narita Y, Shiotsuka M, Kobayashi O, Iwata S, Yoshida A, Abe M, Yamagoe S, Miyazaki Y, Ogawa C. Surgical site infection caused by Rhizopus caespitosus after metastasectomy for osteosarcoma: First report of infection in humans. Pediatric blood & cancer, 70:e30049, 2023

3. Tanaka S, Umezawa J, Yamaji T, Abe SK, Hamada A, Kobayashi O, Ushijima T, Inoue M. SARS-CoV-2 Antibody Response to Symptoms Indicative of COVID-19 in a Non-Infected Population in Japan: a Cross-Sectional Study. Japanese journal of infectious diseases, 76:46-54, 2023

4. Furuichi M, Yaginuma M, Shinjoh M, Ohnishi T, Takahashi T, Iwata S. Extended-Spectrum β-Lactamase-Producing Escherichia coli in Neonates and Listeria monocytogenes in Young Children with Bacterial Meningitis in Japan. Journal of the Pediatric Infectious Diseases Society, 12:165-168, 2023

5. Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine, 41:1834-1847, 2023

6. Katsuta T, Aizawa Y, Shoji K, Shimizu N, Okada K, Nakano T, Kamiya H, Amo K, Ishiwada N, Iwata S, Oshiro M, Okabe N, Korematsu S, Suga S, Tsugawa T, Nishimura N, Hishiki H, Fujioka M, Hosoya M, Mizuno Y, Miyairi I, Miyazaki C, Morishima T, Yoshikawa T, Wada T, Ouchi K, Moriuchi H, Tanaka-Taya K, Saitoh A. Acute and Postacute Clinical Characteristics of Coronavirus Disease 2019 in Children in Japan. The Pediatric infectious disease journal, 42:240-246, 2023

7. Iwata S, Hanada S, Takata M, Morozumi M, Kamei S, Ubukata K. Risk factors and pathogen characteristics associated with unfavorable outcomes among adults with pneumococcal meningitis in Japan, 2006 to 2016. Journal of infection and chemotherapy, 29:637-645, 2023

8. Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine, 40:3721-3726, 2022

9. Takata M, Ubukata K, Miyazaki H, Iwata S, Nakamura S. Diversity of amino acid substitutions of penicillin-binding proteins in penicillin-non-susceptible and non-vaccine type Streptococcus pneumoniae. Journal of infection and chemotherapy, 28:1523-1530, 2022